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To establish whether a feline model can predict nucleoside analogue behavior in human semen, zidovudine
(ZDV) and lamivudine (3TC) pharmacokinetic parameters (PKs) were determined in the blood and seminal
plasma of healthy cats. Our results show considerable similarity in ZDV and 3TC PKs between cats and
humans. As in humans, ZDV and 3TC tend to accumulate in feline seminal plasma. Area under the blood
plasma concentration-time curve was predictive of seminal plasma excretion. The felid model offers a unique
in vivo experimental alternative for investigating the pharmacokinetics of nucleoside analogues in the male
genital tract.
Antiretroviral therapeutics, such as nucleoside and non-
nucleoside reverse transcriptase inhibitors and protease inhib-
itors, have improved the quality of life and life expectancy for
many people infected with human immunodeficiency virus type
1 (HIV-1) (34). Such compounds have also shown promise as
prophylactic alternatives for lowering the risk of acquisition of
new infections in susceptible populations. Most notably, ad-
ministration of zidovudine (ZDV; 39-azido-39-deoxythymidine)
or nevirapine to HIV-1-seropositive pregnant women signifi-
cantly reduces transmission to newborns (6). ZDV treatment
also decreases the risk of HIV-1 infection in occupationally
exposed health care workers (2). There is growing interest in
the efficacy of antiretroviral prophylaxis in the context of ve-
nereal exposure, the most common route of HIV-1 acquisition.
Because ethical and practical constraints may limit direct study
of virus transmission in sexually exposed human populations,
the correlation of appropriate animal model data to human
data offers a valuable avenue for evaluating antiretroviral ther-
apeutic strategies that target virus in genital secretions.
Domestic cats infected with the felid lentivirus feline immu-
nodeficiency virus (FIV) develop an acquired immune defi-
ciency syndrome that parallels the syndrome in HIV-infected
people (24). This small-animal model is a useful and cost-
effective system for the study of lentivirus immunopathogen-
esis and antiviral interventions (4). FIV is susceptible to nu-
cleoside analogues, such as ZDV, zalcitabine, didanosine, and
lamivudine (3TC; b-D-29,39-dideoxy-39-thiacytidine), in vitro at
concentrations similar to those observed with HIV-1 (22, 23,
29, 31). The sensitivities of FIV and HIV-1 to the active
triphosphate forms of ZDV and 3TC are also similar (21, 27).
Furthermore, infected feline patients treated with ZDV show
delayed onset of viremia, reduced plasma virus loads, and
clinical improvement (9–12, 28). 3TC has been studied in vivo
only recently in this species; infected cats receiving experimen-
tal bone marrow transplants and 3TC in combination with
ZDV demonstrated some clinical benefit (36). Because FIV is
shed in semen and can be transmitted by artificial insemination
(15, 16), the feline system may represent a biologically relevant
in vivo alternative for examining the effect of pharmacological
agents on seminal virus transmission. In preparation for testing
the effects of antiretroviral therapy in FIV-infected male cats,
we conducted a preliminary analysis of the pharmacokinetics
(PKs) of a nucleoside analogue combination commonly used in
HIV-1-infected and -exposed individuals, ZDV plus 3TC, in
the blood plasma and seminal plasma of healthy, uninfected
cats.
Three specific-pathogen-free, male domestic cats (Harlan
Sprague Dawley, Inc., Indianapolis, Ind.) were used in this
study. Each cat was 19 months old and weighed approximately
4 kg. The animals were free of disease and were maintained in
accordance with the American Association for Accreditation
of Laboratory Animal Care standards and the “Guide for the
Care and Use of Laboratory Animals” prepared by the Com-
mittee on Care and Use of Laboratory Animals of the Institute
of Laboratory Resources, National Resources Council (20).
ZDV (5 mg/kg of body weight) and 3TC (5 mg/kg) (Glaxo
Wellcome, Inc., Research Triangle Park, N.C.) were com-
pounded together into single-dose capsules and administered
orally every 12 h for 7 days. For blood plasma PK calculations,
up to eight blood plasma samples (e.g., collected at approxi-
mately 0, 0.5, 1, 2, 4, 8, 11, and 12 h postdose) were obtained
by jugular catheterization after dose 1 (day 1, first dose con-
dition) and again after dose 13 (day 7, steady-state condition).
In order to obtain first-dose and steady-state trough concen-
trations (C12) in seminal plasma, four ejaculates were collected
during the 7-day study (e.g., two samples around dose 1 and
two samples around dose 13) by an electroejaculation method
standardized for this species (16). To avoid any confounding
accumulation of drug and to obtain a clean baseline, cats were
ejaculated approximately 1 h before dose 1 and dose 13 (C21).
Cats were ejaculated again 12 h after dose 1 and dose 13, but
prior to doses 2 and 14, respectively. A fifth semen sample was
collected from cat 1 at 1 h after dose 9 by artificial vagina as
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described previously (30). Blood plasma and seminal plasma
specimens were separated from cellular constituents by cen-
trifugation at 2,000 3 g for 10 min and stored at 270°C until
assayed.
Drug concentrations were determined by liquid chromatog-
raphy and tandem mass spectroscopy as described by Pereira et
al. (26). PK parameters were obtained by noncompartmental
analyses using WinNonlin (version 3.0; Pharsight Corp.,
Mountain View, Calif.), and statistics were analyzed with SAS
JMP 3.2.1 software (SAS Institute, Cary, N.C.) using nonpara-
metric methods (with Bonferroni’s correction for multiple
comparisons; P , 0.01). Anemia has been reported as a side
effect of nucleoside analogue administration in cats (primarily
at doses higher than those used in this study) (7, 8, 10); there-
fore, packed cell volumes were determined at days 0 and 7.
PK data for each drug in feline blood plasma obtained dur-
ing the first 12 h and steady-state 12-h intervals are summa-
rized in Table 1. Blood plasma PK values from studies of
healthy human volunteers are included for comparison (Com-
bivir; Zidovudine and Lamivudine Product Information, 2000,
Glaxo Wellcome, Inc., Research Triangle Park, N.C.; C. Cre-
mieux, C. Katlama, H. Prevot, S. Leclerc, C. Gillotin, D. De-
marles, P. Vial, and F. Raffi, Abstr. XIIIth Int. AIDS Conf.,
abstr. 4125, 2000; references 19 and 35). The cats remained
healthy during the study and anemia was not observed. In
blood plasma, the C12 values for ZDV and 3TC did not differ
significantly between first dose and steady state in the cats (P .
0.25); the median value (range) for AZT C12 at first dose was
68.8 ng/ml (31.7 to 102.4 ng/ml) and 79.5 ng/ml (46.3 to 152.4
ng/ml) at steady state, and the C12 values for 3TC were 164.0
ng/ml (38.7 to 173.4 ng/ml) at first dose and 244.5 ng/ml (99.3
to 273.9 ng/ml) at steady state.
In this study of seronegative cats receiving ZDV in combi-
nation with 3TC, ZDV blood plasma PKs were similar to those
reported in uninfected cats given ZDV alone (7, 10), suggest-
ing that, as in people, 3TC coadministration did not substan-
tially alter ZDV PK (19). 3TC PK data have not been reported
previously for this species. Comparisons of time to maximum
drug concentration (Tmax) values in Table 1 indicate that these
nucleoside analogues are rapidly absorbed in cats and humans
after oral administration, with maximal blood plasma concen-
trations (Cmax) attained within approximately 1.5 h. ZDV is
eliminated primarily by the hepatic glucuronidation pathway,
and the higher Cmax, higher area under the curve (AUC), and
lower clearance (CLF) observed in cats as compared with hu-
mans may be related, in part, to deficiencies in glucuronidation
in feline species (3). ZDV half-life (t1/2) and VF were somewhat
lower in cats than in humans. Feline 3TC blood plasma Cmax
and AUC were higher in cats than in humans. This may reflect
the higher dose administered to the cats. The CLF values were
similar between species, though the feline 3TC VF was greater
than seen in humans, resulting in a shorter calculated plasma
t1/2. Unlike ZDV, 3TC undergoes minimal metabolism and is
eliminated via renal secretion (14).
The C12 values for ZDV and 3TC in feline semen are shown
in Fig. 1. The mean 6 standard deviation for the seminal
plasma concentration of ZDV was 58.9 6 69.4 ng/ml after the
first dose and 45.1 6 12.2 ng/ml at steady state. For 3TC,
seminal plasma drug concentrations were 66.5 6 92.7 ng/ml
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reason for the very high concentrations observed in cat 3 at
first dose is uncertain. In general, variability in parent drug
concentration was similar to what has been described in hu-
mans (25). The formation of semen is complex and the com-
position of ejaculated fluid is highly modified as it passes
through secretory tissues. Correcting for ejaculate volume, the
total amount of drug excreted in the feline ejaculates (seminal
plasma drug concentration ejaculate volume) demonstrated a
tendency toward accumulation at steady state (Fig. 2). Indeed,
after an extended time without ejaculation (Fig. 3), concentra-
tions were usually higher than those observed during the two
12-h collection periods, indicating that in cats, like humans (1,
13, 25), accumulation in this biological compartment extends
beyond a single dosing interval. Systemic drug exposure over a
dosing interval in the cats, as measured by AUC (Table 1) was
positively correlated with seminal plasma excretion (Spear-
man’s correlation coefficient, 0.67, P 5 0.03), suggesting that
approximately 40% of the variability in semen drug concentra-
tions can be explained by systemic exposure to ZDV and 3TC.
In a human study that analyzed serial paired semen and
blood specimens obtained up to 500 days posttreatment, it was
apparent that ZDV and 3TC can attain much higher concen-
trations in semen relative to blood (25). Median human sem-
inal plasma to blood plasma (SP/BP) ratios for ZDV and 3TC
were 5.9 (range, 1.0 to 13.5) and 9.1 (range, 2.3 to 16.1), re-
spectively, supporting the sequestration or selective transport
of nucleoside analogues into the seminal compartment, a char-
acteristic that lends support for the administration of these
drugs to prevent sexual spread of infection. In cats, median
SP/BP ratios were also .1 in specimens collected more than 12
h after a previous ejaculation; the median SP/BP ratios were
3.01 (range, 2.55 to 220.30) for ZDV and 1.33 (range, 1.04 to
45.04) for 3TC.
Penetration of antiretroviral agents in the genital compart-
ment is highly variable, not only between subjects but also
between different compounds. Like ZDV and 3TC, stavudine,
efavirenz, and nevirapine achieve seminal drug concentrations
above the 50% inhibitory concentration for HIV-1. In contrast,
the protease inhibitors saquinavir and ritonavir achieve low-
to-undetectable concentrations (32, 33; J. Kim, K. Gotzkowksy,
J. Eron, D. Manion, W. Fiske, M. Cohen, and A. Kashuba,
Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother.,
abstr. 1171, 2000). Thus, drug exposure in genital secretions
cannot be predicted solely on the basis of physicochemical
properties, such as plasma protein binding, partition coeffi-
cients, and dissociation constants (17). To avoid suboptimal
drug levels that could permit covert virus replication in the
reproductive tract and dissemination of drug-resistant isolates
(5), PK modeling for specific compounds or combination of
compounds is essential. Relevant animal models suitable for
assessing the potential pharmacological prevention of HIV-1
sexual transmission are limited. There are no rodent lentivirus
systems that mirror the clinicopathologic effects of HIV-1.
Simian immunodeficiency virus causes AIDS in rhesus ma-
caques and closely approximates the virologic characteristics of
HIV-1, but seminal plasma from this species frequently forms
an insoluble coagulum precluding sample analysis. In cats,
seminal plasma can be easily collected and this study confirms
for the first time that nucleoside analogues can be quantified in
this compartment in this small-animal species.
Like most animal models, there are limitations in using cats
FIG. 1. Trough concentrations (C12, in nanograms per milliliter) of
ZDV and 3TC in seminal plasma from domestic cats after first dose
(day 1) and at steady state (day 7).
FIG. 2. The excretion (seminal plasma volume times trough drug
concentration, in nanograms) of ZDV and 3TC in ejaculates from
domestic cats after first dose and steady state.
FIG. 3. Log graph of trough concentrations (C12, in nanograms per
milliliter) of ZDV (open symbols) and 3TC (solid symbols) in feline
seminal plasma with increasing time between semen collection. Semen
was collected from all cats during day 1 and day 7; semen was also
collected from cat 1 during day 5.
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to address semen antiviral characteristics, and more detailed
comparisons of the PK properties of these compounds and
their triphosphorylated metabolites are warranted to fully val-
idate this model. As noted earlier, felids have a low capacity for
hepatic glucuronidation of drug metabolites (3). Anatomically,
the feline and human genital tracts differ. Nearly 70% of hu-
man seminal plasma forms in the seminal vesicles, but cats, like
other carnivores, lack this accessory organ. In addition, the ejac-
ulate volume in cats is quite small (50 to 350 ml), limiting some
types of analyses. Although FIV is susceptible to nucleoside an-
alogues, it is not susceptible to currently prescribed HIV-1 pro-
tease inhibitors. This is a rapidly evolving area, however, and
protease inhibitors active against both viruses are under devel-
opment (18). Despite these differences, our results show con-
siderable similarity in ZDV and 3TC PKs in humans and cats,
suggesting that the feline system may be useful for experimen-
tal investigation of antiviral agents in the male genital tract.
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